Next Article in Journal
Aedes albopictus Autophagy-Related Gene 8 (AaAtg8) Is Required to Confer Anti-Bacterial Gut Immunity
Previous Article in Journal
Multiple Sclerosis Treatment and Melanoma Development
Previous Article in Special Issue
Evaluation of Antioxidant Activity of Spice-Derived Phytochemicals Using Zebrafish
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 21
Issue 8
10.3390/ijms21082951
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Roles of Nrf2 in Protecting the Kidney from Oxidative Damage

by
Masahiro Nezu
1,2 and
Norio Suzuki
2,*
1
Department of Endocrinology and Diabetes, Yamanashi Prefectural Central Hospital, Fujimi 1-1-1, Kofu, Japan
2
Division of Oxygen Biology, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Aoba-ku, Sendai, Japan
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(8), 2951; https://doi.org/10.3390/ijms21082951
Submission received: 18 March 2020 / Revised: 16 April 2020 / Accepted: 21 April 2020 / Published: 22 April 2020
(This article belongs to the Special Issue The Nrf2 Pathway: Regulation, Functions, and Potential Applications)
Browse Figures
Review Reports Versions Notes

Abstract

:
Over 10% of the global population suffers from kidney disease. However, only kidney replacement therapies, which burden medical expenses, are currently effective in treating kidney disease. Therefore, elucidating the complicated molecular pathology of kidney disease is an urgent priority for developing innovative therapeutics for kidney disease. Recent studies demonstrated that intertwined renal vasculature often causes ischemia-reperfusion injury (IRI), which generates oxidative stress, and that the accumulation of oxidative stress is a common pathway underlying various types of kidney disease. We reported that activating the antioxidative transcription factor Nrf2 in renal tubules in mice with renal IRI effectively mitigates tubular damage and interstitial fibrosis by inducing the expression of genes related to cytoprotection against oxidative stress. Additionally, since the kidney performs multiple functions beyond blood purification, renoprotection by Nrf2 activation is anticipated to lead to various benefits. Indeed, our experiments indicated the possibility that Nrf2 activation mitigates anemia, which is caused by impaired production of the erythroid growth factor erythropoietin from injured kidneys, and moderates organ damage worsened by anemic hypoxia. Clinical trials investigating Nrf2-activating compounds in kidney disease patients are ongoing, and beneficial effects are being obtained. Thus, Nrf2 activators are expected to emerge as first-in-class innovative medicine for kidney disease treatment.

1. Introduction

The kidneys are two organs located in the retroperitoneal space and function not only to purify blood but also to control blood pressure by producing the vasopressor renin, to maintain bone mineral homeostasis by activating vitamin D, and to produce the erythroid growth factor erythropoietin (Epo). Therefore, kidney injuries provoke fluid-balance abnormalities, uremia, hypertension, born-mineral disorders and anemia [1]. Although more than 850 million people worldwide suffer from kidney disease, which carries a considerable burden of medical expenses in many countries [2], no effective medicine for treating kidney disease has been established due to the lack of knowledge of the molecular pathology of multifactorial renal failure. Thus, elucidation of the molecular mechanisms of kidney disease progression is urgently needed.
Among the different types of renal failure, acute kidney injury (AKI) [3] and chronic kidney disease (CKD) are the major syndromes [4]. AKI is defined as an abrupt reduction in renal function within a few days or weeks [5], while CKD is defined by the presence of kidney damage or decreased kidney function for three or more months [6]. Restoration of kidney structure and recovery of renal function are often observed in AKI patients [7], even though AKI is associated with poor mortality [8]. Patients suffering from AKI bear a heightened risk of disease progression to CKD followed by end-stage renal disease (ESRD), which is the final common clinical feature of renal failure [9]. For patients with ESRD, renal replacement therapies, including hemodialysis, peritoneal dialysis and kidney transplantation, are fundamentally unavoidable [10]. On the other hand, considering that AKI and CKD interact with each other, it is known that patients with CKD bear a higher risk of developing AKI [11].
For kidney functions such as reabsorption and humoral factor secretion, kidneys are rich in capillaries compared with other organs. Renal capillaries are considered to be easily damaged by hyperglycemia and hypertension, the major causes of kidney disease, and capillary damage provokes IRI [12]. Since IRI generates oxidative stress, which is involved in various diseases, it is plausible that a reduction in oxidative stress could block kidney disease progression. Indeed, activators of Nrf2 (nuclear factor erythroid 2-related factor 2; a member of the Cap ‘n’ Collar [CNC] transcription factor family), which is the master regulator of antioxidant genes [13,14], are investigated in ongoing clinical trials as medicines for treating kidney disease [15,16,17]. The Nrf2 activators currently in development are compounds that inhibit Keap1 (Kelch-like ECH-associated protein 1), which negatively regulates Nrf2 under conditions free from oxidative stress [14,18]. In this review, we introduce the molecular functions of Keap1 and Nrf2 in kidney disease as well as up-to-date information on the development of drugs targeting the Keap1–Nrf2 system for kidney disease treatment.

2. Oxidative Stress in Kidney

Renal tubular epithelial cells actively and constitutively produce adenosine triphosphate for reabsorption of water and solutes from pre-urine, consuming oxygen by the abundant mitochondria [19]. Mitochondrial respiration also produces reactive oxygen species, which are highly reactive to biomolecules, including genomic DNA. Low-level reactive oxygen species (ROS) are essential for intra- and intercellular signaling to maintain kidney homeostasis and function, including vascular reactivity, renal hemodynamics, glomerular filtration, tubular reabsorption and hormonal secretion, while excessive ROS are detrimental to renal cells by leading to oxidative stress [20].
To deliver oxygen into the kidneys via blood flow, approximately 20–25% of the cardiac output is allocated to the kidneys, which is significantly high considering the size of the kidneys compared to that of other organs [21]. However, the characteristics of the renal vasculature forming many arterial-to-venous shunts often cause irregular blood flow and IRI [21]. In the reperfusion phase of renal IRI, ROS are produced by the mitochondrial respiration chain and/or nicotinamide adenine dinucleotide phosphate (NADPH) oxidases [3,21,22]. In addition to ROS, the accumulation of electrophilic molecules triggers oxidative stress. Interestingly, an electrophilic molecule, 15-deoxy-∆12,14)-prostaglandin J2, is produced by convoluted blood flow with shear stress and activates Nrf2 in endothelial cells [23].
Excessive ROS and electrophiles impair cellular homeostasis and function as oxidative stress followed by cell death, which leads to inflammation, tissue damage and fibrosis (Figure 1) [14,20]. Inflammatory cells, which are locally activated in the renal microenvironment or migrate from hematopoietic organs, further produce ROS. Thus, oxidative stress, as with inflammation, is regarded to be a key aggravating factor for the initiation and progression of AKI and CKD, including diabetic nephropathy, hypertension-associated kidney disease and toxic-induced nephropathy [18,20,24]. In these types of kidney disease, electrophiles accumulate as byproducts of impaired detoxification and abnormal metabolism and aggravate oxidative stress, making matters worse [25,26]. Therefore, defense against oxidative stress is regarded as an important therapeutic target for preventing kidney disease progression.

3. Role of the Keap1-Nrf2 System in Cytoprotection against Oxidative Stress

To protect cells from harmful oxidative stress, the transcription factor Nrf2 plays an integrative role in inducing the expression of genes encoding enzymes involved in antioxidant (e.g., glutathione and NADPH) production and the reduction in pro-oxidants (e.g., heme and quinonoids, Figure 2) [14,18]. In unstressed cells, Nrf2 is constitutively synthesized but degraded by the Nrf2-specific ubiquitin ligase complex, in which the stress-sensor molecule Keap1 directly captures Nrf2 (Figure 2). A Keap1 molecule contains reactive cysteines, which are adducted by oxidants and electrophiles, to sense cellular oxidative stress. Since cysteine-modified Keap1 no longer binds to Nrf2, Nrf2 avoids degradation and activates the expression of its target genes under oxidative stress conditions [14,18].
Several proteins have been identified as essential transcriptional cofactors directly binding to Nrf2 in nuclei. The heterodimer formation of Nrf2 with one of the small Maf (musculoaponeurotic fibrosarcoma) proteins (MafF, MafG, and MafK) is necessary for Nrf2 binding to CsMBE (CNC and small Maf binding element, 5′-(A/G)TGA(G/C)nnnGC) located in promoters or enhancers of Nrf2-target genes (Figure 2) [27]. In addition to DNA-binding factors, such as small Maf proteins, cyclic AMP-response element binding protein (CREB)-binding protein (CBP), brahma-related gene 1 (BRG1), and chromodomain helicase DNA binding protein 6 (CHD6) are involved in transcriptional activation of genes related to cytoprotection against oxidative stress by directly binding to Nrf2 (Figure 2) [27,28,29,30]. Additionally, we previously discovered that the transcriptional mediator complex contributes to antioxidant gene expression via a direct interaction between Nrf2 and a mediator subunit, MED16 (Figure 2) [31].

4. Mouse Genetic Models Used to Investigate the Roles of Nrf2 in the Kidney

Systemic Nrf2 knockout (Nrf2-KO) mice exhibit no abnormalities at birth, during growth, with fertility or throughout their lifespan under normal conditions [32], whereas analyses of Nrf2-KO mice with various disease models have demonstrated that Nrf2 plays protective roles against respiratory disease [33,34,35,36], cardiac disease [37], neurological disease [38,39], diabetes mellitus [40,41,42,43], obesity [44], sickle-cell disease [45], inflammation [46,47], infection [48], liver disease [49,50,51,52] and sensory organ diseases [53,54,55]. Additionally, in kidney disease models such as autoimmune nephritis [56], diabetic nephropathy [57,58,59], toxic injury [60,61,62], ureteral obstruction [63], podocyte injury [64] and IRI [61,63,64,65,66,67], the loss of Nrf2 aggravates tissue damage and fibrosis (Table 1).
On the other hand, systemic Keap1 knockout (Keap1-KO) mice starve to death during the weaning period because of impaired feeding due to hyperkeratosis of the upper gastrointestinal tract, suggesting that Nrf2 induces the expression of genes encoding keratin [68]. Indeed, genetic deletion of Nrf2 in keratinocytes rescues Keap1-KO mice from lethal hyperkeratosis [69]. However, most of the rescued mice die within 10 months after birth due to polyuria and dehydration caused by an abnormal renal structure resembling hydronephrosis. Keap1 gene deletion exclusively in renal tubular epithelial cells of mouse embryos also induced polyuria and hydronephrosis after birth [69,70]. These results indicate that constitutive activation of Nrf2 in renal tubules of developing kidneys hinders the development and function of the kidneys (Table 1). In contrast, adult-onset deletion of the Keap1 gene exclusively in renal tubular cells caused no abnormalities in renal structure or function [67], demonstrating that overactivation of Nrf2 in the mature renal epithelium makes kidneys resistant to oxidative injuries without any significant abnormalities. These results are consistent with the results from Nrf2-KO mice, which suggest that Nrf2 is necessary for renoprotection from injuries as described above (Table 1).

5. Mechanism of Renoprotection by Nrf2

Our mouse analyses have demonstrated that 8-hydroxydeoxyguanosine (8-OHdG), one of the oxidative DNA adducts and a marker for oxidative injury, accumulates in renal tubules of the outer medulla 24 h after renal IRI surgery [67]. The outer medullary areas positive for 8-OHdG, in which necrosis and apoptosis are also observed, expand to the renal cortex for seven days after injury, followed by interstitial fibrosis. These observations suggest that oxidative stress is one of the triggers for kidney disease and that quenching oxidative stress by Nrf2 activation in tubules is a plausible strategy for preventing kidney damage. In fact, systemic activation of Nrf2 in Keap1 hypomorphic mutant (Keap1 knockdown; Keap1-KD) mice significantly attenuates 8-OHdG accumulation and mitigates kidney damage progression compared to wild-type mice (Table 1) [67]. On the other hand, the Nrf2-KO mice exhibited more severe 8-OHdG accumulation and more severe tubular damage than the wild-type mice (Table 1).
Oxidative stress provoked by IRI immediately and slightly induces the expression of Nrf2-target genes in wild-type kidneys, but the induction is transient and returns to basal levels within 24 h after injury [67]. Therefore, it is suggested that Nrf2 is swiftly activated in response to the oxidative stress induced by renal IRI, but the activation is insufficient to eliminate cytotoxic stress. Additionally, the oxidative stress response system governed by Nrf2 is likely impaired due to cellular oxidative damage, as previous articles reported that Nrf2 is inactivated in chronically damaged kidneys [73]. In accordance with the theory of the Keap1-Nrf2 system, Keap1-KD mice showed significantly mild pathology of tubular damage, interstitial fibrosis and renal dysfunction (increased serum creatinine level) compared to wild-type mice (Table 1 and Figure 3A) [67].
The renoprotective effect of Nrf2 activation in systemic Keap1-KD mice is nicely recapitulated in a gene-modified mouse line in which the Keap1 gene is deleted exclusively in adult renal tubular cells (Table 1 and Figure 3A) [67]. However, Keap1 deletion in mouse myeloid cells, which accumulate in the tubular interstitium of injured kidneys, shows no protective effect on kidney damage. Thus, tubular epithelial cells, but not myeloid cells, are responsible for the Nrf2-mediated renoprotection against oxidative stress. T lymphocytes also accumulate in the interstitia of injured kidneys in response to renal oxidative stress and participate in renal inflammation (Table 1) [66]. Intriguingly, since deletion of the Keap1 gene in mouse T lymphocytes mitigates kidney damage caused by IRI, T lymphocytes are also suggested to be involved in Nrf2-mediated renoprotection from oxidative stress [66].
In tumor cells, Nrf2 plays an important role in cell proliferation by activating the pentose phosphate pathway (PPP), which provides nucleotides for genomic replication of mitotic tumor cells and the antioxidant NADPH for cytoprotection from oxidative stress provoked by the tumor environment [74]. Consistently, both the NADPH concentrations and the expression levels of PPP genes such as G6PD and PGD (encoding glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase, respectively) in Keap1-KD kidneys are higher than those in wild-type kidneys, and the levels are further elevated by IRI [67]. However, no differences in renal cell proliferation after IRI were observed among the Keap1-KD, Nrf2-KO and wild-type mice. Therefore, we propose that PPP activation by Nrf2 is associated with renoprotection from oxidative injury, but not cell proliferation, by producing the antioxidant NADPH. Nrf2 also induces glutathione-related genes, including GSTM1 and GCLM (encoding glutathione S-transferase µ1 and glutamate-cysteine ligase modifier subunit, respectively), and matrix-assisted laser desorption/ionization-imaging mass spectrometry has demonstrated that compared to wild-type mice, glutathione is highly produced in the cortex and outer medulla in Keap1-KD mice before and after IRI [67]. Because the tubules in the renal cortex and outer medulla are vulnerable to oxidative injury (Figure 3A), glutathione production in these tissues is considered significant for kidney protection from IRI. Consequently, enhancing the production of antioxidants such as NADPH and glutathione in tubular cells is considered the major mechanism of Nrf2-mediated renoprotection from IRI (Figure 4A).

6. Beneficial Effects of Nrf2 Activation for Kidney Disease Treatment

Since numerous mouse genetic studies have demonstrated the beneficial effects of Nrf2 activation on the prevention of kidney disease (Table 1), basic research and clinical trials of chemical compounds activating Nrf2 are being conducted (Table 2). Above all, 1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]-imidazolide (CDDO-imidazolide), which is a semisynthetic triterpenoid from natural products that inhibits association between Nrf2 and Keap1 by directly binding to Keap1, is one of the most predominant compounds activating Nrf2 [75,76,77]. Oral administration of CDDO-imidazolide every two days after IRI dramatically mitigates kidney damage in mice (Figure 3B) [67]. Importantly, our data from mouse experiments propose that immediate (within 24 h) initiation of treatment with CDDO-imidazolide is essential for protection of the kidneys from oxidative damage (Figure 3B) [67].
While most reports concerning Nrf2 function in the kidney highlight beneficial effects of Nrf2 activation, several reports note its negative roles. In mouse models of autoimmune nephritis and diabetic nephropathy, Nrf2 deficiency ameliorates the disease phenotype (Table 1) [71,72]. Additionally, pharmacological Nrf2 activation worsens diabetic nephropathy in rats [78]. Although the use of Nrf2 activators in clinical trials successfully improved the estimated glomerular filtration rate (eGFR) in patients with diabetic nephropathy, increased albuminuria was observed [16]. Moreover, Nrf2 activation has been found in kidney cancers and is considered involved in cancer progression [79,80,81]. Thus, Nrf2 activation does not always lead to positive effects on kidney diseases.
In addition to urine production, the kidney produces and secretes the erythroid growth factor Epo in interstitial fibroblasts referred to as “REP (renal Epo-producing) cells” [103]. Therefore, kidney injury often causes anemia as a complication of CKD through inactivation of renal Epo production (Figure 1) [104,105]. Recent reports have suggested that Epo-deficiency anemia further aggravates kidney damage [106,107]. In fact, our mouse model for Epo-deficiency anemia [108] demonstrates that tubular damage and fibrosis are more severe than those in the control mice after unilateral renal IRI (Figure 4B and C). Although the aggravating mechanism is still controversial, enhanced oxidative stress resulting from reduced oxygen delivery (hypoxia) due to anemia, IRI due to sparse erythrocytes in renal capillaries, and/or retardation of iron utilization for hemoglobin synthesis are considered the major causes (Figure 1). Additionally, loss of Epo, which may directly protect renal cells from injury [109,110], may devastate renal damage in Epo-deficient anemic mice.
We found that CDDO-imidazolide enhances the anemia-induced activity of Epo-gene expression in the kidneys from anemic mice (Figure 4D). Since enhancement is not observed in normal kidneys, it is proposed that renal Epo gene expression is not fully induced by anemia due to anemia-provoked oxidative stress. Additionally, we propose that Nrf2 activation potentially mitigates Epo deficiency in injured kidneys, which is led by oxidative stress, although additional experiments are required to confirm this conclusion. Taken together, Nrf2 activators are thought to protect kidneys from oxidative damage via induction of antioxidant genes and prevention of Epo deficiency by intervening in the negative spiral consisting of oxidative stress and tubular damage (Figure 4A).

7. Clinical Impact of Pharmacological Activation of Nrf2 on Kidney Injury

Based on cumulative evidence of beneficial effects of Nrf2 activators on kidney disease treatment, CDDO-methyl ester (CDDO-ME, also known as RTA402 or bardoxolone methyl; Table 2) has been undergoing clinical trials for the treatment of CKD with type 2 diabetes mellitus [15,16]. At first, in 2006, CDDO-ME was expected to be an antitumor agent and was tested in a phase I clinical trial for solid cancer and hematological malignancy [112]. Unexpectedly, the trial demonstrated that CDDO-ME dramatically (26%) increased the eGFR of subjects suffering from kidney disease as a complication. Since then, CDDO-ME has been investigated to develop novel medicines against diabetic nephropathy, for which no effective medicine has been established despite its high morbidity [113,114]. The phase II trials of CDDO-ME, one of which has also been known as the BEAM study, confirmed that CDDO-ME dramatically improves eGFR (Table 3) [15].
Then, a phase III clinical trial (referred to as the BEACON study) was conducted with 2185 patients belonging to the second most severe CKD stage (Grade 4) [115]. Although the BEACON study showed a significant increase in eGFR by 5.5 mL/min/1.73 m2 in the group treated with 20 mg/day CDDO-ME, this clinical trial was terminated in 2012 because of the high incidence of cardiovascular events, especially heart failure, in the group treated with CDDO-ME (Table 3) [16]. Most of the CDDO-ME subjects also exhibited fluid retention with an increase in blood pressure, heart rate, and serum brain natriuretic peptide (BNP) in addition to a decrease in blood concentrations of albumin and hemoglobin compared to the placebo subjects. Accordingly, it has been considered that the cardiac function of patients with very poor renal function is likely vulnerable to fluid overload, which may be related to CDDO-ME administration [116]. Indeed, no imbalance in cardiovascular events was observed between the CDDO-ME and placebo subjects in the BEAM study, in which the subjects suffered from milder stages of CKD (Grade 3b and 4) than those in the BEACON study (Grade 4). Moreover, basal serum BNP concentrations, which are well correlated with fluid retention, in the CDDO-ME subjects were less than 200 pg/mL, and the incidence of cardiac failure among these subjects was comparable to that among the placebo subjects in the BEACON study [116].
In 2015, a phase II randomized double-blind, placebo-controlled clinical trial of CDDO-ME was restarted with 120 CKD patients of Grade 3 or 4, excluding patients bearing risk factors for fluid overload (e.g., high-level BNP and history of heart failure), and the results nicely showed a significant increase in eGFR without any signs of fluid overload (TSUBAKI study; Table 3) [17,18]. In 2018, a phase III randomized controlled clinical trial referred to as the AYAME study (https://clinicaltrials.gov/ct2/show/NCT03550443) was launched with diabetic CKD patients whose CKD stages are Grade 3 or 4 as a successor to the phase II study in Japan. The primary endpoint is the time to onset of a more than 30% decrease in eGFR from baseline. The AYAME study will be completed in 2022, and the data are expected to clearly determine the clinical benefits of CDDO-ME in patients suffering from diabetic nephropathy [117].
In addition to diabetic nephropathy, clinical trials of CDDO-ME for the treatment of various other types of kidney disease are currently being conducted or prepared. For example, the CARDINAL study (phase II/III, 2017–2020, https://clinicaltrials.gov/ct2/show/NCT03019185) and the FALCON study (phase III, 2019–2023, https://clinicaltrials.gov/ct2/show/NCT03918447) are ongoing with patients suffering from Alport syndrome (a hereditary progressive renal disease caused by abnormal type IV collagen) and ADPKD (autosomal dominant polycystic kidney disease), respectively [118,119]. Additionally, the long-term safety and tolerability of CDDO-ME for CKD patients are being estimated by the EAGLE study (phase III, 2019–2024, https://clinicaltrials.gov/ct2/show/NCT03749447). These clinical trials are based on the profound function of Nrf2 in renoprotection, and reducing oxidative stress by Nrf2 activation is expected to mitigate a variety of diseases beyond kidney disease.

8. Conclusions and Perspective

Currently, approximately 10% of the worldwide population suffers from kidney disease, and the burden of medical expenses due to kidney disease is increasing in many countries because only transplantation or hemodialysis are available for treating kidney disease. Therefore, CDDO-ME and other Nrf2 activators are earnestly anticipated as first-in-class medicine for kidney disease treatment, and the clinical trials introduced above are receiving considerable attention. Basic studies of the Nrf2 pathway have demonstrated multiple cytoprotective functions of Nrf2 and unveiled regulatory mechanisms of Nrf2 activity in response to oxidative stress. Recent studies have shown that activated Nrf2 in nuclei is degraded through βTrCP-mediated ubiquitination to avoid overactivation of Nrf2 [90,99,120], supporting the safety of chemical compounds activating Nrf2 for patients. Because oxidative stress is a primary factor for tissue damage in every organ, pharmacologically driving the antioxidative response system by Nrf2 activators is plausible for curing a variety of diseases.

Author Contributions

Conceptualization and writing, M.N. and N.S. Both authors have read and agreed to the published version of the manuscript.

Funding

This research was partially funded by Chugai Pharmaceutical Co. Ltd., Daiichi Sankyo Foundation of Life Science, Takeda Life Science Foundation and SENSHIN Medical Research Foundation with research contracts. The funders have no role in this study.

Acknowledgments

We thank Masayuki Yamamoto (Tohoku University) and Michinori Hirata (Chugai Pharmaceutical Co. Ltd.) for giving us professional comments.

Conflicts of Interest

The other authors declare no conflicts of interest.

Abbreviations

8-OHdG8-hydroxydeoxyguanosine
AKIacute kidney injury
BRG1brahma-related gene 1
CBPcyclic AMP-response element binding protein (CREB)-binding protein
CDDO1-[2-cyano-3-,12-dioxooleana-1,9(11)-dien-28-oyl]
CHD6chromodomain helicase DNA binding protein 6
CKDchronic kidney disease
CNCCap ‘n’ Collar
CPT1Acarnitine palmitoyltransferase 1A
CsMBECNC and small Maf binding element
DAMPsdamage-associated molecular patterns
eGFRestimated glomerular filtration rate
Epoerythropoietin
ESRDend-stage renal disease
G6PDglucose-6-phosphate dehydrogenase 6
GCLCglutamate cysteine ligase catalytic subunit
GCLMglutamate cysteine ligase modifier subunit
GFPgreen fluorescent protein
GSTM1glutathione S-transferase µ1
HMOX1heme oxygenase 1
IRIischemia-reperfusion injury
Keap1Kelch-like ECH-associated protein 1
ME1malic enzyme 1
MED16mediator subunit 16
MTHFD2methylenetetrahydrofolate dehydrogenase 2
NADPHnicotinamide adenine dinucleotide phosphate
NQO1NADPH quinone oxidoreductase 1
NRF1nuclear respiratory factor 1
Nrf2nuclear factor erythroid 2-related factor 2
PGD6-phosphogluconate dehydrogenase
PPPpentose phosphate pathway
REP cellrenal Epo-producing cell
ROSreactive oxygen species
sMafsmall musculoaponeurotic fibrosarcoma
TXNRD1thioredoxin reductase 1

References

  1. Sato, Y.; Yanagita, M. Renal anemia: From incurable to curable. Am. J. Physiol. Renal Physiol. 2013, 305, F1239–F1248. [Google Scholar] [CrossRef] [Green Version]
  2. Jager, K.J.; Kovesdy, C.; Langham, R.; Rosenberg, M.; Jha, V.; Zoccali, C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019, 96, 1048–1050. [Google Scholar] [CrossRef]
  3. Ohsaki, Y.; O’Connor, P.; Mori, T.; Ryan, R.P.; Dickinson, B.C.; Chang, C.J.; Lu, Y.; Ito, S.; Cowley, A.W., Jr. Increase of sodium delivery stimulates the mitochondrial respiratory chain H2O2 production in rat renal medullary thick ascending limb. Am. J. Physiol. Renal Physiol. 2012, 302, F95–F102. [Google Scholar] [CrossRef] [Green Version]
  4. Levey, A.S.; Eckardt, K.U.; Tsukamoto, Y.; Levin, A.; Coresh, J.; Rossert, J.; De Zeeuw, D.; Hostetter, T.H.; Lameire, N.; Eknoyan, G. Definition and classification of chronic kidney disease: A position statement from kidney disease: Improving global outcomes (KDIGO). Kidney Int. 2005, 67, 2089–2100. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Summary of Recommendation Statements. Kidney Int. Suppl. 2012, 2, 8–12. [CrossRef] [PubMed] [Green Version]
  6. Chapter 1: Definition and classification of CKD. Kidney Int. Suppl. 2013, 3, 19–62. [CrossRef] [PubMed] [Green Version]
  7. Humphreys, B.D.; Cantaluppi, V.; Portilla, D.; Singbartl, K.; Yang, L.; Rosner, M.H.; Kellum, J.A.; Ronco, C.; Acute Dialysis Quality Initiative, X.W.G. Targeting endogenous repair pathways after AKI. J. Am. Soc. Nephrol. 2016, 27, 990–998. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  8. Susantitaphong, P.; Cruz, D.N.; Cerda, J.; Abulfaraj, M.; Alqahtani, F.; Koulouridis, I.; Jaber, B.L. Acute Kidney Injury Advisory Group of the American Society of, N. World incidence of AKI: A meta-analysis. Clin. J. Am. Soc. Nephrol. 2013, 8, 1482–1493. [Google Scholar] [CrossRef] [Green Version]
  9. Murtagh, F.E.; Burns, A.; Moranne, O.; Morton, R.L.; Naicker, S. Supportive care: Comprehensive conservative care in end-stage kidney disease. Clin. J. Am. Soc. Nephrol. 2016, 11, 1909–1914. [Google Scholar] [CrossRef] [Green Version]
  10. Lo, L.J.; Go, A.S.; Chertow, G.M.; McCulloch, C.E.; Fan, D.; Ordonez, J.D.; Hsu, C.Y. Dialysis-requiring acute renal failure increases the risk of progressive chronic kidney disease. Kidney Int. 2009, 76, 893–899. [Google Scholar] [CrossRef] [Green Version]
  11. He, L.; Wei, Q.; Liu, J.; Yi, M.; Liu, Y.; Liu, H.; Sun, L.; Peng, Y.; Liu, F.; Venkatachalam, M.A.; et al. AKI on CKD: Heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017, 92, 1071–1083. [Google Scholar] [CrossRef] [PubMed]
  12. Basile, D.P. The endothelial cell in ischemic acute kidney injury: Implications for acute and chronic function. Kidney Int. 2007, 72, 151–156. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Itoh, K.; Chiba, T.; Takahashi, S.; Ishii, T.; Igarashi, K.; Katoh, Y.; Oyake, T.; Hayashi, N.; Satoh, K.; Hatayama, I.; et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236, 313–322. [Google Scholar] [CrossRef] [PubMed]
  14. Yamamoto, M.; Kensler, T.W.; Motohashi, H. The KEAP1-NRF2 System: A thiol-based sensor-effector apparatus for maintaining redox homeostasis. Physiol. Rev. 2018, 98, 1169–1203. [Google Scholar] [CrossRef] [Green Version]
  15. Pergola, P.E.; Raskin, P.; Toto, R.D.; Meyer, C.J.; Huff, J.W.; Grossman, E.B.; Krauth, M.; Ruiz, S.; Audhya, P.; Christ-Schmidt, H.; et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N. Engl. J. Med. 2011, 365, 327–336. [Google Scholar] [CrossRef] [Green Version]
  16. de Zeeuw, D.; Akizawa, T.; Audhya, P.; Bakris, G.L.; Chin, M.; Christ-Schmidt, H.; Goldsberry, A.; Houser, M.; Krauth, M.; Lambers Heerspink, H.J.; et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N. Engl. J. Med. 2013, 369, 2492–2503. [Google Scholar] [CrossRef] [Green Version]
  17. Ito, M.; Tanaka, T.; Nangaku, M. Nuclear factor erythroid 2-related factor 2 as a treatment target of kidney diseases. Curr. Opin. Nephrol. Hypertens. 2020, 29, 128–135. [Google Scholar] [CrossRef]
  18. Nezu, M.; Suzuki, N.; Yamamoto, M. Targeting the KEAP1-NRF2 system to prevent kidney disease progression. Am. J. Nephrol. 2017, 45, 473–483. [Google Scholar] [CrossRef]
  19. Rolfe, D.F.; Brown, G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol. Rev. 1997, 77, 731–758. [Google Scholar] [CrossRef] [Green Version]
  20. Ratliff, B.B.; Abdulmahdi, W.; Pawar, R.; Wolin, M.S. Oxidant mechanisms in renal injury and disease. Antioxid. Redox. Signal. 2016, 25, 119–146. [Google Scholar] [CrossRef] [Green Version]
  21. Layton, A.T. Recent advances in renal hypoxia: Insights from bench experiments and computer simulations. Am. J. Physiol. Renal Physiol. 2016, 311, F162–F165. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  22. Quijano, C.; Castro, L.; Peluffo, G.; Valez, V.; Radi, R. Enhanced mitochondrial superoxide in hyperglycemic endothelial cells: Direct measurements and formation of hydrogen peroxide and peroxynitrite. Am. J. Physiol. Heart Circ. Physiol. 2007, 293, H3404–H3414. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  23. Hosoya, T.; Maruyama, A.; Kang, M.I.; Kawatani, Y.; Shibata, T.; Uchida, K.; Warabi, E.; Noguchi, N.; Itoh, K.; Yamamoto, M. Differential responses of the Nrf2-Keap1 system to laminar and oscillatory shear stresses in endothelial cells. J. Biol. Chem. 2005, 280, 27244–27250. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  24. Forbes, J.M.; Coughlan, M.T.; Cooper, M.E. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes 2008, 57, 1446–1454. [Google Scholar] [CrossRef] [Green Version]
  25. Rodrigues, S.D.; Santos, S.S.; Meireles, T.; Romero, N.; Glorieux, G.; Pecoits-Filho, R.; Zhang, D.D.; Nakao, L.S. Uremic toxins promote accumulation of oxidized protein and increased sensitivity to hydrogen peroxide in endothelial cells by impairing the autophagic flux. Biochem. Biophys. Res. Commun. 2020, 523, 123–129. [Google Scholar] [CrossRef] [Green Version]
  26. Popkov, V.A.; Silachev, D.N.; Zalevsky, A.O.; Zorov, D.B.; Plotnikov, E.Y. Mitochondria as a source and a target for uremic toxins. Int. J. Mol. Sci. 2019, 20, 3094. [Google Scholar] [CrossRef] [Green Version]
  27. Otsuki, A.; Suzuki, M.; Katsuoka, F.; Tsuchida, K.; Suda, H.; Morita, M.; Shimizu, R.; Yamamoto, M. Unique cistrome defined as CsMBE is strictly required for Nrf2-sMaf heterodimer function in cytoprotection. Free Radic. Biol. Med. 2016, 91, 45–57. [Google Scholar] [CrossRef] [Green Version]
  28. Katoh, Y.; Itoh, K.; Yoshida, E.; Miyagishi, M.; Fukamizu, A.; Yamamoto, M. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 2001, 6, 857–868. [Google Scholar] [CrossRef]
  29. Zhang, J.; Hosoya, T.; Maruyama, A.; Nishikawa, K.; Maher, J.M.; Ohta, T.; Motohashi, H.; Fukamizu, A.; Shibahara, S.; Itoh, K.; et al. Nrf2 Neh5 domain is differentially utilized in the transactivation of cytoprotective genes. Biochem. J. 2007, 404, 459–466. [Google Scholar] [CrossRef] [Green Version]
  30. Nioi, P.; Nguyen, T.; Sherratt, P.J.; Pickett, C.B. The carboxy-terminal Neh3 domain of Nrf2 is required for transcriptional activation. Mol. Cell. Biol. 2005, 25, 10895–10906. [Google Scholar] [CrossRef] [Green Version]
  31. Sekine, H.; Okazaki, K.; Ota, N.; Shima, H.; Katoh, Y.; Suzuki, N.; Igarashi, K.; Ito, M.; Motohashi, H.; Yamamoto, M. The mediator subunit MED16 transduces NRF2-activating signals into antioxidant gene expression. Mol. Cell. Biol. 2015, 36, 407–420. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Chan, K.; Lu, R.; Chang, J.C.; Kan, Y.W. NRF2, a member of the NFE2 family of transcription factors, is not essential for murine erythropoiesis, growth, and development. Proc. Natl. Acad. Sci. USA 1996, 93, 13943–13948. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Cho, H.Y.; Gladwell, W.; Yamamoto, M.; Kleeberger, S.R. Exacerbated airway toxicity of environmental oxidant ozone in mice deficient in Nrf2. Oxid. Med. Cell. Longev. 2013, 2013, 254069. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Sussan, T.E.; Gajghate, S.; Chatterjee, S.; Mandke, P.; McCormick, S.; Sudini, K.; Kumar, S.; Breysse, P.N.; Diette, G.B.; Sidhaye, V.K.; et al. Nrf2 reduces allergic asthma in mice through enhanced airway epithelial cytoprotective function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2015, 309, L27–L36. [Google Scholar] [CrossRef] [Green Version]
  35. Nagashima, R.; Kosai, H.; Masuo, M.; Izumiyama, K.; Noshikawaji, T.; Morimoto, M.; Kumaki, S.; Miyazaki, Y.; Motohashi, H.; Yamamoto, M.; et al. Nrf2 suppresses allergic lung inflammation by attenuating the type 2 innate lymphoid cell response. J. Immunol. 2019, 202, 1331–1339. [Google Scholar] [CrossRef] [PubMed]
  36. Eba, S.; Hoshikawa, Y.; Moriguchi, T.; Mitsuishi, Y.; Satoh, H.; Ishida, K.; Watanabe, T.; Shimizu, T.; Shimokawa, H.; Okada, Y.; et al. The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice. Am. J. Respir. Cell. Mol. Biol. 2013, 49, 324–333. [Google Scholar] [CrossRef] [Green Version]
  37. Katsumata, Y.; Shinmura, K.; Sugiura, Y.; Tohyama, S.; Matsuhashi, T.; Ito, H.; Yan, X.; Ito, K.; Yuasa, S.; Ieda, M.; et al. Endogenous prostaglandin D2 and its metabolites protect the heart against ischemia-reperfusion injury by activating Nrf2. Hypertension 2014, 63, 80–87. [Google Scholar] [CrossRef] [Green Version]
  38. Linker, R.A.; Lee, D.H.; Ryan, S.; van Dam, A.M.; Conrad, R.; Bista, P.; Zeng, W.; Hronowsky, X.; Buko, A.; Chollate, S.; et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011, 134, 678–692. [Google Scholar] [CrossRef] [Green Version]
  39. Uruno, A.; Matsumaru, D.; Ryoke, R.; Saito, R.; Kadoguchi, S.; Saigusa, D.; Saito, T.; Saido, T.C.; Kawashima, R.; Yamamoto, M. Nrf2 suppresses oxidative stress and inflammation in App knock-in Alzheimer’s disease model mice. Mol. Cell. Biol. 2020, 40, e00467-19. [Google Scholar] [CrossRef]
  40. Uruno, A.; Furusawa, Y.; Yagishita, Y.; Fukutomi, T.; Muramatsu, H.; Negishi, T.; Sugawara, A.; Kensler, T.W.; Yamamoto, M. The Keap1-Nrf2 system prevents onset of diabetes mellitus. Mol. Cell. Biol. 2013, 33, 2996–3010. [Google Scholar] [CrossRef] [Green Version]
  41. Yagishita, Y.; Fukutomi, T.; Sugawara, A.; Kawamura, H.; Takahashi, T.; Pi, J.; Uruno, A.; Yamamoto, M. Nrf2 protects pancreatic beta-cells from oxidative and nitrosative stress in diabetic model mice. Diabetes 2014, 63, 605–618. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Yagishita, Y.; Uruno, A.; Chartoumpekis, D.V.; Kensler, T.W.; Yamamoto, M. Nrf2 represses the onset of type 1 diabetes in non-obese diabetic mice. J. Endocrinol. 2019. [Google Scholar] [CrossRef] [PubMed]
  43. Yagishita, Y.; Uruno, A.; Fukutomi, T.; Saito, R.; Saigusa, D.; Pi, J.; Fukamizu, A.; Sugiyama, F.; Takahashi, S.; Yamamoto, M. Nrf2 Improves Leptin and Insulin Resistance Provoked by Hypothalamic Oxidative Stress. Cell Rep. 2017, 18, 2030–2044. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Shin, S.; Wakabayashi, J.; Yates, M.S.; Wakabayashi, N.; Dolan, P.M.; Aja, S.; Liby, K.T.; Sporn, M.B.; Yamamoto, M.; Kensler, T.W. Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-imidazolide. Eur. J. Pharmacol. 2009, 620, 138–144. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Keleku-Lukwete, N.; Suzuki, M.; Otsuki, A.; Tsuchida, K.; Katayama, S.; Hayashi, M.; Naganuma, E.; Moriguchi, T.; Tanabe, O.; Engel, J.D.; et al. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation. Proc. Natl. Acad. Sci. USA 2015, 112, 12169–12174. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  46. Itoh, K.; Mochizuki, M.; Ishii, Y.; Ishii, T.; Shibata, T.; Kawamoto, Y.; Kelly, V.; Sekizawa, K.; Uchida, K.; Yamamoto, M. Transcription factor Nrf2 regulates inflammation by mediating the effect of 15-deoxy-Delta(12,14)-prostaglandin j(2). Mol. Cell. Biol. 2004, 24, 36–45. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  47. Maicas, N.; Ferrandiz, M.L.; Brines, R.; Ibanez, L.; Cuadrado, A.; Koenders, M.I.; van den Berg, W.B.; Alcaraz, M.J. Deficiency of Nrf2 accelerates the effector phase of arthritis and aggravates joint disease. Antioxid. Redox. Signal. 2011, 15, 889–901. [Google Scholar] [CrossRef] [Green Version]
  48. Thimmulappa, R.K.; Lee, H.; Rangasamy, T.; Reddy, S.P.; Yamamoto, M.; Kensler, T.W.; Biswal, S. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J. Clin. Investig. 2006, 116, 984–995. [Google Scholar] [CrossRef] [Green Version]
  49. Enomoto, A.; Itoh, K.; Nagayoshi, E.; Haruta, J.; Kimura, T.; O’Connor, T.; Harada, T.; Yamamoto, M. High sensitivity of Nrf2 knockout mice to acetaminophen hepatotoxicity associated with decreased expression of ARE-regulated drug metabolizing enzymes and antioxidant genes. Toxicol. Sci. 2001, 59, 169–177. [Google Scholar] [CrossRef] [Green Version]
  50. Taguchi, K.; Masui, S.; Itoh, T.; Miyajima, A.; Yamamoto, M. Nrf2 activation ameliorates hepatotoxicity induced by a heme synthesis inhibitor. Toxicol. Sci. 2019, 167, 227–238. [Google Scholar] [CrossRef]
  51. Skoko, J.J.; Wakabayashi, N.; Noda, K.; Kimura, S.; Tobita, K.; Shigemura, N.; Tsujita, T.; Yamamoto, M.; Kensler, T.W. Loss of Nrf2 in mice evokes a congenital intrahepatic shunt that alters hepatic oxygen and protein expression gradients and toxicity. Toxicol. Sci. 2014, 141, 112–119. [Google Scholar] [CrossRef] [PubMed]
  52. Okada, K.; Warabi, E.; Sugimoto, H.; Horie, M.; Gotoh, N.; Tokushige, K.; Hashimoto, E.; Utsunomiya, H.; Takahashi, H.; Ishii, T.; et al. Deletion of Nrf2 leads to rapid progression of steatohepatitis in mice fed atherogenic plus high-fat diet. J. Gastroenterol. 2013, 48, 620–632. [Google Scholar] [CrossRef] [PubMed]
  53. Knatko, E.V.; Ibbotson, S.H.; Zhang, Y.; Higgins, M.; Fahey, J.W.; Talalay, P.; Dawe, R.S.; Ferguson, J.; Huang, J.T.; Clarke, R.; et al. Nrf2 activation protects against solar-simulated ultraviolet radiation in mice and humans. Cancer Prev. Res (Phila.) 2015, 8, 475–486. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  54. Xu, Z.; Wei, Y.; Gong, J.; Cho, H.; Park, J.K.; Sung, E.R.; Huang, H.; Wu, L.; Eberhart, C.; Handa, J.T.; et al. NRF2 plays a protective role in diabetic retinopathy in mice. Diabetologia 2014, 57, 204–213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Honkura, Y.; Matsuo, H.; Murakami, S.; Sakiyama, M.; Mizutari, K.; Shiotani, A.; Yamamoto, M.; Morita, I.; Shinomiya, N.; Kawase, T.; et al. NRF2 is a key target for prevention of noise-induced hearing loss by reducing oxidative damage of cochlea. Sci. Rep. 2016, 6, 19329. [Google Scholar] [CrossRef] [Green Version]
  56. Ma, Q.; Battelli, L.; Hubbs, A.F. Multiorgan autoimmune inflammation, enhanced lymphoproliferation, and impaired homeostasis of reactive oxygen species in mice lacking the antioxidant-activated transcription factor Nrf2. Am. J. Pathol. 2006, 168, 1960–1974. [Google Scholar] [CrossRef] [Green Version]
  57. Yoh, K.; Hirayama, A.; Ishizaki, K.; Yamada, A.; Takeuchi, M.; Yamagishi, S.; Morito, N.; Nakano, T.; Ojima, M.; Shimohata, H.; et al. Hyperglycemia induces oxidative and nitrosative stress and increases renal functional impairment in Nrf2-deficient mice. Genes Cells 2008, 13, 1159–1170. [Google Scholar] [CrossRef]
  58. Jiang, T.; Huang, Z.; Lin, Y.; Zhang, Z.; Fang, D.; Zhang, D.D. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes 2010, 59, 850–860. [Google Scholar] [CrossRef] [Green Version]
  59. Zheng, H.; Whitman, S.A.; Wu, W.; Wondrak, G.T.; Wong, P.K.; Fang, D.; Zhang, D.D. Therapeutic potential of Nrf2 activators in streptozotocin-induced diabetic nephropathy. Diabetes 2011, 60, 3055–3066. [Google Scholar] [CrossRef] [Green Version]
  60. Tanaka, Y.; Aleksunes, L.M.; Goedken, M.J.; Chen, C.; Reisman, S.A.; Manautou, J.E.; Klaassen, C.D. Coordinated induction of Nrf2 target genes protects against iron nitrilotriacetate (FeNTA)-induced nephrotoxicity. Toxicol. Appl. Pharmacol. 2008, 231, 364–373. [Google Scholar] [CrossRef] [Green Version]
  61. Liu, M.; Grigoryev, D.N.; Crow, M.T.; Haas, M.; Yamamoto, M.; Reddy, S.P.; Rabb, H. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009, 76, 277–285. [Google Scholar] [CrossRef] [Green Version]
  62. Aleksunes, L.M.; Goedken, M.J.; Rockwell, C.E.; Thomale, J.; Manautou, J.E.; Klaassen, C.D. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatin-induced nephrotoxicity. J. Pharmacol. Exp. Ther. 2010, 335, 2–12. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Tan, R.J.; Chartoumpekis, D.V.; Rush, B.M.; Zhou, D.; Fu, H.; Kensler, T.W.; Liu, Y. Keap1 hypomorphism protects against ischemic and obstructive kidney disease. Sci. Rep. 2016, 6, 36185. [Google Scholar] [CrossRef] [PubMed]
  64. Miyazaki, Y.; Shimizu, A.; Pastan, I.; Taguchi, K.; Naganuma, E.; Suzuki, T.; Hosoya, T.; Yokoo, T.; Saito, A.; Miyata, T.; et al. Keap1 inhibition attenuates glomerulosclerosis. Nephrol. Dial. Transpl. 2014, 29, 783–791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Liu, M.; Reddy, N.M.; Higbee, E.M.; Potteti, H.R.; Noel, S.; Racusen, L.; Kensler, T.W.; Sporn, M.B.; Reddy, S.P.; Rabb, H. The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia-reperfusion injury in mice. Kidney Int. 2014, 85, 134–141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  66. Noel, S.; Martina, M.N.; Bandapalle, S.; Racusen, L.C.; Potteti, H.R.; Hamad, A.R.; Reddy, S.P.; Rabb, H. T Lymphocyte-Specific Activation of Nrf2 Protects from AKI. J. Am. Soc. Nephrol. 2015, 26, 2989–3000. [Google Scholar] [CrossRef] [Green Version]
  67. Nezu, M.; Souma, T.; Yu, L.; Suzuki, T.; Saigusa, D.; Ito, S.; Suzuki, N.; Yamamoto, M. Transcription factor Nrf2 hyperactivation in early-phase renal ischemia-reperfusion injury prevents tubular damage progression. Kidney Int. 2017, 91, 387–401. [Google Scholar] [CrossRef]
  68. Wakabayashi, N.; Itoh, K.; Wakabayashi, J.; Motohashi, H.; Noda, S.; Takahashi, S.; Imakado, S.; Kotsuji, T.; Otsuka, F.; Roop, D.R.; et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 2003, 35, 238–245. [Google Scholar] [CrossRef]
  69. Suzuki, T.; Seki, S.; Hiramoto, K.; Naganuma, E.; Kobayashi, E.H.; Yamaoka, A.; Baird, L.; Takahashi, N.; Sato, H.; Yamamoto, M. Hyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus. Nat. Commun. 2017, 8, 14577. [Google Scholar] [CrossRef] [Green Version]
  70. Noel, S.; Arend, L.J.; Bandapalle, S.; Reddy, S.P.; Rabb, H. Kidney epithelium specific deletion of kelch-like ECH-associated protein 1 (Keap1) causes hydronephrosis in mice. BMC Nephrol. 2016, 17, 110. [Google Scholar] [CrossRef] [Green Version]
  71. Morito, N.; Yoh, K.; Hirayama, A.; Itoh, K.; Nose, M.; Koyama, A.; Yamamoto, M.; Takahashi, S. Nrf2 deficiency improves autoimmune nephritis caused by the fas mutation lpr. Kidney Int. 2004, 65, 1703–1713. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  72. Zhao, S.; Ghosh, A.; Lo, C.S.; Chenier, I.; Scholey, J.W.; Filep, J.G.; Ingelfinger, J.R.; Zhang, S.L.; Chan, J.S.D. Nrf2 deficiency upregulates intrarenal angiotensin-converting enzyme-2 and angiotensin 1-7 receptor expression and attenuates hypertension and nephropathy in diabetic mice. Endocrinology 2018, 159, 836–852. [Google Scholar] [CrossRef] [PubMed]
  73. Aminzadeh, M.A.; Nicholas, S.B.; Norris, K.C.; Vaziri, N.D. Role of impaired Nrf2 activation in the pathogenesis of oxidative stress and inflammation in chronic tubulo-interstitial nephropathy. Nephrol. Dial. Transpl. 2013, 28, 2038–2045. [Google Scholar] [CrossRef] [PubMed]
  74. Mitsuishi, Y.; Taguchi, K.; Kawatani, Y.; Shibata, T.; Nukiwa, T.; Aburatani, H.; Yamamoto, M.; Motohashi, H. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012, 22, 66–79. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  75. Dinkova-Kostova, A.T.; Liby, K.T.; Stephenson, K.K.; Holtzclaw, W.D.; Gao, X.; Suh, N.; Williams, C.; Risingsong, R.; Honda, T.; Gribble, G.W.; et al. Extremely potent triterpenoid inducers of the phase 2 response: Correlations of protection against oxidant and inflammatory stress. Proc. Natl. Acad. Sci. USA 2005, 102, 4584–4589. [Google Scholar] [CrossRef] [Green Version]
  76. Ruiz, S.; Pergola, P.E.; Zager, R.A.; Vaziri, N.D. Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease. Kidney Int. 2013, 83, 1029–1041. [Google Scholar] [CrossRef] [Green Version]
  77. Sporn, M.B.; Liby, K.T.; Yore, M.M.; Fu, L.; Lopchuk, J.M.; Gribble, G.W. New synthetic triterpenoids: Potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress. J. Nat. Prod. 2011, 74, 537–545. [Google Scholar] [CrossRef]
  78. Zoja, C.; Corna, D.; Nava, V.; Locatelli, M.; Abbate, M.; Gaspari, F.; Carrara, F.; Sangalli, F.; Remuzzi, G.; Benigni, A. Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. Am. J. Physiol. Renal Physiol. 2013, 304, F808–F819. [Google Scholar] [CrossRef] [Green Version]
  79. Ooi, A.; Wong, J.C.; Petillo, D.; Roossien, D.; Perrier-Trudova, V.; Whitten, D.; Min, B.W.; Tan, M.H.; Zhang, Z.; Yang, X.J. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell. 2011, 20, 511–523. [Google Scholar] [CrossRef] [Green Version]
  80. Adam, J.; Hatipoglu, E.; O’Flaherty, L.; Ternette, N.; Sahgal, N.; Lockstone, H.; Baban, D.; Nye, E.; Stamp, G.W.; Wolhuter, K.; et al. Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: Roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell. 2011, 20, 524–537. [Google Scholar] [CrossRef] [Green Version]
  81. Kovac, M.; Navas, C.; Horswell, S.; Salm, M.; Bardella, C.; Rowan, A.; Stares, M.; Castro-Giner, F.; Fisher, R.; de Bruin, E.C.; et al. Recurrent chromosomal gains and heterogeneous driver mutations characterise papillary renal cancer evolution. Nat. Commun. 2015, 6, 6336. [Google Scholar] [CrossRef] [PubMed]
  82. Wu, Q.Q.; Wang, Y.; Senitko, M.; Meyer, C.; Wigley, W.C.; Ferguson, D.A.; Grossman, E.; Chen, J.; Zhou, X.J.; Hartono, J.; et al. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. Am. J. Physiol. Renal Physiol. 2011, 300, F1180–F1192. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  83. Wu, J.; Liu, X.; Fan, J.; Chen, W.; Wang, J.; Zeng, Y.; Feng, X.; Yu, X.; Yang, X. Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway. Toxicology 2014, 318, 22–31. [Google Scholar] [CrossRef] [PubMed]
  84. Nagasu, H.; Sogawa, Y.; Kidokoro, K.; Itano, S.; Yamamoto, T.; Satoh, M.; Sasaki, T.; Suzuki, T.; Yamamoto, M.; Wigley, W.C.; et al. Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function. FASEB J. 2019, 33, 12253–12263. [Google Scholar] [CrossRef] [Green Version]
  85. Molina-Jijón, E.; Tapia, E.; Zazueta, C.; El Hafidi, M.; Zatarain-Barrón, Z.L.; Hernández-Pando, R.; Medina-Campos, O.N.; Zarco-Márquez, G.; Torres, I.; Pedraza-Chaverri, J. Curcumin prevents Cr(VI)-induced renal oxidant damage by a mitochondrial pathway. Free Radic. Biol. Med. 2011, 51, 1543–1557. [Google Scholar] [CrossRef]
  86. Tapia, E.; Soto, V.; Ortiz-Vega, K.M.; Zarco-Márquez, G.; Molina-Jijón, E.; Cristóbal-García, M.; Santamaría, J.; García-Niño, W.R.; Correa, F.; Zazueta, C.; et al. Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats. Oxid. Med. Cell. Longev. 2012, 2012, 269039. [Google Scholar] [CrossRef] [Green Version]
  87. Wu, J.; Pan, X.; Fu, H.; Zheng, Y.; Dai, Y.; Yin, Y.; Chen, Q.; Hao, Q.; Bao, D.; Hou, D. Effect of curcumin on glycerol-induced acute kidney injury in rats. Sci. Rep. 2017, 7, 10114. [Google Scholar] [CrossRef] [Green Version]
  88. Li, Y.; Zhang, J.; Liu, H.; Yuan, J.; Yin, Y.; Wang, T.; Cheng, B.; Sun, S.; Guo, Z. Curcumin ameliorates glyoxylate-induced calcium oxalate deposition and renal injuries in mice. Phytomedicine 2019, 61, 152861. [Google Scholar] [CrossRef]
  89. Jin, F.; Chen, X.; Yan, H.; Xu, Z.; Yang, B.; Luo, P.; He, Q. Bisdemethoxycurcumin attenuates cisplatin-induced renal injury through anti-apoptosis, anti-oxidant and anti-inflammatory. Eur. J. Pharmacol. 2020, 874, 173026. [Google Scholar] [CrossRef]
  90. Feng, X.; Guan, W.; Zhao, Y.; Wang, C.; Song, M.; Yao, Y.; Yang, T.; Fan, H. Dexmedetomidine ameliorates lipopolysaccharide-induced acute kidney injury in rats by inhibiting inflammation and oxidative stress via the GSK-3β/Nrf2 signaling pathway. J. Cell Physiol. 2019, 234, 18994–19009. [Google Scholar] [CrossRef]
  91. Zhu, J.; Wang, Q.; Li, C.; Lu, Y.; Hu, H.; Qin, B.; Xun, Y.; Zhu, Y.; Wu, Y.; Zhang, J.; et al. Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate. Free Radic. Biol. Med. 2019, 134, 9–22. [Google Scholar] [CrossRef]
  92. Oh, C.J.; Kim, J.Y.; Choi, Y.K.; Kim, H.J.; Jeong, J.Y.; Bae, K.H.; Park, K.G.; Lee, I.K. Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-β/Smad signaling. PLoS ONE 2012, 7, e45870. [Google Scholar] [CrossRef] [PubMed]
  93. Ma, N.; Wei, W.; Fan, X.; Ci, X. Farrerol attenuates cisplatin-induced nephrotoxicity by inhibiting the reactive oxygen species-mediated oxidation, inflammation, and apoptotic signaling pathways. Front. Physiol. 2019, 10, 1419. [Google Scholar] [CrossRef] [PubMed]
  94. Han, P.; Qin, Z.; Tang, J.; Xu, Z.; Li, R.; Jiang, X.; Yang, C.; Xing, Q.; Qi, X.; Tang, M.; et al. RTA-408 protects kidney from ischemia-reperfusion injury in mice via activating Nrf2 and Downstream GSH Biosynthesis gene. Oxid. Med. Cell. Longev. 2017, 2017, 7612182. [Google Scholar] [CrossRef] [PubMed]
  95. Wu, J.; Xu, L.; Sun, C.; Zhang, B.; Li, J.; Sun, J.; Zhang, Y.; Sun, D. Paeonol alleviates epirubicin-induced renal injury in mice by regulating Nrf2 and NF-κB pathways. Eur. J. Pharmacol. 2017, 795, 84–93. [Google Scholar] [CrossRef] [PubMed]
  96. Li, J.; Li, L.; Wang, S.; Zhang, C.; Zheng, L.; Jia, Y.; Xu, M.; Zhu, T.; Zhang, Y.; Rong, R. Resveratrol alleviates inflammatory responses and oxidative stress in rat kidney ischemia-reperfusion injury and H2O2-induced NRK-52E cells via the Nrf2/TLR4/NF-κB pathway. Cell Physiol. Biochem. 2018, 45, 1677–1689. [Google Scholar] [CrossRef]
  97. Kim, E.N.; Lim, J.H.; Kim, M.Y.; Ban, T.H.; Jang, I.A.; Yoon, H.E.; Park, C.W.; Chang, Y.S.; Choi, B.S. Resveratrol, an Nrf2 activator, ameliorates aging-related progressive renal injury. Aging (Albany NY) 2018, 10, 83–99. [Google Scholar] [CrossRef] [Green Version]
  98. Li, X.; Zou, Y.; Xing, J.; Fu, Y.Y.; Wang, K.Y.; Wan, P.Z.; Zhai, X.Y. Pretreatment with roxadustat (FG-4592) attenuates folic acid-induced kidney injury through antiferroptosis via Akt/GSK-3β/Nrf2 pathway. Oxid. Med. Cell. Longev. 2020, 2020, 6286984. [Google Scholar] [CrossRef] [Green Version]
  99. Zhou, S.; Wang, P.; Qiao, Y.; Ge, Y.; Wang, Y.; Quan, S.; Yao, R.; Zhuang, S.; Wang, L.J.; Du, Y.; et al. Genetic and pharmacologic targeting of glycogen synthase kinase 3β reinforces the Nrf2 antioxidant defense against podocytopathy. J. Am. Soc Nephrol. 2016, 27, 2289–2308. [Google Scholar] [CrossRef] [Green Version]
  100. Zhao, Z.; Liao, G.; Zhou, Q.; Lv, D.; Holthfer, H.; Zou, H. Sulforaphane attenuates contrast-induced nephropathy in rats via Nrf2/HO-1 pathway. Oxid. Med. Cell. Longev. 2016, 2016, 9825623. [Google Scholar] [CrossRef]
  101. Yoon, H.Y.; Kang, N.I.; Lee, H.K.; Jang, K.Y.; Park, J.W.; Park, B.H. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem. Pharmacol. 2008, 75, 2214–2223. [Google Scholar] [CrossRef] [PubMed]
  102. Jiang, T.; Tian, F.; Zheng, H.; Whitman, S.A.; Lin, Y.; Zhang, Z.; Zhang, N.; Zhang, D.D. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney Int. 2014, 85, 333–343. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  103. Suzuki, N.; Yamamoto, M. Roles of renal erythropoietin-producing (REP) cells in the maintenance of systemic oxygen homeostasis. Pflugers Arch. 2016, 468, 3–12. [Google Scholar] [CrossRef] [PubMed]
  104. Souma, T.; Yamazaki, S.; Moriguchi, T.; Suzuki, N.; Hirano, I.; Pan, X.; Minegishi, N.; Abe, M.; Kiyomoto, H.; Ito, S.; et al. Plasticity of renal erythropoietin-producing cells governs fibrosis. J. Am. Soc. Nephrol. 2013, 24, 1599–1616. [Google Scholar] [CrossRef] [Green Version]
  105. Souma, T.; Nezu, M.; Nakano, D.; Yamazaki, S.; Hirano, I.; Sekine, H.; Dan, T.; Takeda, K.; Fong, G.H.; Nishiyama, A.; et al. Erythropoietin synthesis in renal myofibroblasts is restored by activation of hypoxia signaling. J. Am. Soc. Nephrol. 2016, 27, 428–438. [Google Scholar] [CrossRef]
  106. Gouva, C.; Nikolopoulos, P.; Ioannidis, J.P.; Siamopoulos, K.C. Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial. Kidney Int. 2004, 66, 753–760. [Google Scholar] [CrossRef] [Green Version]
  107. Rodrigues, C.E.; Sanches, T.R.; Volpini, R.A.; Shimizu, M.H.; Kuriki, P.S.; Camara, N.O.; Seguro, A.C.; Andrade, L. Effects of continuous erythropoietin receptor activator in sepsis-induced acute kidney injury and multi-organ dysfunction. PLoS ONE 2012, 7, e29893. [Google Scholar] [CrossRef] [Green Version]
  108. Yamazaki, S.; Souma, T.; Hirano, I.; Pan, X.; Minegishi, N.; Suzuki, N.; Yamamoto, M. A mouse model of adult-onset anaemia due to erythropoietin deficiency. Nat. Commun. 2013, 4, 1950. [Google Scholar] [CrossRef] [Green Version]
  109. Westenfelder, C.; Biddle, D.L.; Baranowski, R.L. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int. 1999, 55, 808–820. [Google Scholar] [CrossRef] [Green Version]
  110. Zhang, Y.; Wang, L.; Dey, S.; Alnaeeli, M.; Suresh, S.; Rogers, H.; Teng, R.; Noguchi, C.T. Erythropoietin action in stress response, tissue maintenance and metabolism. Int. J. Mol. Sci. 2014, 15, 10296–10333. [Google Scholar] [CrossRef] [Green Version]
  111. Suzuki, N.; Sasaki, Y.; Kato, K.; Yamazaki, S.; Kurasawa, M.; Yorozu, K.; Shimonaka, Y.; Yamamoto, M. Efficacy estimation of erythropoiesis-stimulating agents using erythropoietin-deficient anemic mice. Haematologica 2016, 101, e356–e360. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  112. Hong, D.S.; Kurzrock, R.; Supko, J.G.; He, X.; Naing, A.; Wheler, J.; Lawrence, D.; Eder, J.P.; Meyer, C.J.; Ferguson, D.A.; et al. A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2012, 18, 3396–3406. [Google Scholar] [CrossRef] [Green Version]
  113. Afkarian, M.; Sachs, M.C.; Kestenbaum, B.; Hirsch, I.B.; Tuttle, K.R.; Himmelfarb, J.; de Boer, I.H. Kidney disease and increased mortality risk in type 2 diabetes. J. Am. Soc. Nephrol. 2013, 24, 302–308. [Google Scholar] [CrossRef] [PubMed]
  114. Fox, C.S.; Matsushita, K.; Woodward, M.; Bilo, H.J.; Chalmers, J.; Heerspink, H.J.; Lee, B.J.; Perkins, R.M.; Rossing, P.; Sairenchi, T.; et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis. Lancet 2012, 380, 1662–1673. [Google Scholar] [CrossRef] [Green Version]
  115. de Zeeuw, D.; Akizawa, T.; Agarwal, R.; Audhya, P.; Bakris, G.L.; Chin, M.; Krauth, M.; Lambers Heerspink, H.J.; Meyer, C.J.; McMurray, J.J.; et al. Rationale and trial design of bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes: The occurrence of renal events (BEACON). Am. J. Nephrol. 2013, 37, 212–222. [Google Scholar] [CrossRef] [PubMed]
  116. Chin, M.P.; Wrolstad, D.; Bakris, G.L.; Chertow, G.M.; de Zeeuw, D.; Goldsberry, A.; Linde, P.G.; McCullough, P.A.; McMurray, J.J.; Wittes, J.; et al. Risk factors for heart failure in patients with type 2 diabetes mellitus and stage 4 chronic kidney disease treated with bardoxolone methyl. J. Card. Fail. 2014, 20, 953–958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  117. Yamawaki, K.; Kanda, H.; Shimazaki, R. Nrf2 activator for the treatment of kidney diseases. Toxicol. Appl. Pharmacol. 2018, 360, 30–37. [Google Scholar] [CrossRef]
  118. Kashtan, C.E.; Ding, J.; Garosi, G.; Heidet, L.; Massella, L.; Nakanishi, K.; Nozu, K.; Renieri, A.; Rheault, M.; Wang, F.; et al. Alport syndrome: A unified classification of genetic disorders of collagen IV alpha345: A position paper of the Alport Syndrome Classification Working Group. Kidney Int. 2018, 93, 1045–1051. [Google Scholar] [CrossRef]
  119. Chapman, A.B.; Devuyst, O.; Eckardt, K.U.; Gansevoort, R.T.; Harris, T.; Horie, S.; Kasiske, B.L.; Odland, D.; Pei, Y.; Perrone, R.D.; et al. Autosomal-dominant polycystic kidney disease (ADPKD): Executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2015, 88, 17–27. [Google Scholar] [CrossRef] [Green Version]
  120. Rada, P.; Rojo, A.I.; Chowdhry, S.; McMahon, M.; Hayes, J.D.; Cuadrado, A. SCF/βTrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol. Cell. Biol. 2011, 31, 1121–1133. [Google Scholar] [CrossRef] [Green Version]
Ijms 21 02951 g001 550
Figure 1. Oxidative stress and kidney disease. Irregular blood flow in the renal capillaries (red) provokes ischemia-reperfusion injury (IRI), followed by the emergence of ROS and electrophiles, which are causes of oxidative stress. Accumulated oxidative stress injures epithelial cells of renal tubules (orange), and damaged cells scatter damage-associated molecular patterns (DAMPs) and inflammatory cytokines. Tubular damage induces inflammation mediated by myeloid cells (purple) as well as transformation of interstitial fibroblasts (green) into myofibroblasts that promote kidney fibrosis. The myofibroblastic transformation impairs Epo production by renal interstitial fibroblasts (also known as REP [renal Epo-producing] cells) and causes renal anemia. Anemia and inflammation further enhance oxidative stress in kidneys.
Figure 1. Oxidative stress and kidney disease. Irregular blood flow in the renal capillaries (red) provokes ischemia-reperfusion injury (IRI), followed by the emergence of ROS and electrophiles, which are causes of oxidative stress. Accumulated oxidative stress injures epithelial cells of renal tubules (orange), and damaged cells scatter damage-associated molecular patterns (DAMPs) and inflammatory cytokines. Tubular damage induces inflammation mediated by myeloid cells (purple) as well as transformation of interstitial fibroblasts (green) into myofibroblasts that promote kidney fibrosis. The myofibroblastic transformation impairs Epo production by renal interstitial fibroblasts (also known as REP [renal Epo-producing] cells) and causes renal anemia. Anemia and inflammation further enhance oxidative stress in kidneys.
Ijms 21 02951 g001
Ijms 21 02951 g002 550
Figure 2. The molecular mechanism by which Nrf2 induces the expression of genes involved in cytoprotection against oxidative stress. In cells free of oxidative stress, the newly synthesized Nrf2 protein is directly captured by the Keap1 homodimer and degraded through the ubiquitin-proteasome pathway. Under oxidative stress conditions, Nrf2 avoids Keap1-mediated degradation because Keap1 is denatured by ROS or electrophiles (e). Stabilized Nrf2 is translocated into the nucleus and forms heterodimers with small Maf (sMaf) proteins, enabling binding to CsMBE in the promoters or enhancers of antioxidant genes (listed in the red box); transcription of these genes is induced by the Nrf2 complex containing CBP, BRG1, CHD6, and MED16. HMOX1, heme oxygenase 1; NQO1, NADPH quinone oxidoreductase 1; TXNRD1, thioredoxin reductase 1; G6PD, glucose-6-phosphate dehydrogenase; PGD, 6-phosphogluconate dehydrogenase; ME1, malic enzyme 1; GCLC, glutamate cysteine ligase catalytic subunit; GCLM, glutamate cysteine ligase modifier subunit; GSTM1, glutathione S-transferase µ1; CPT1A, carnitine palmitoyltransferase 1A; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; NRF1, nuclear respiratory factor 1.
Figure 2. The molecular mechanism by which Nrf2 induces the expression of genes involved in cytoprotection against oxidative stress. In cells free of oxidative stress, the newly synthesized Nrf2 protein is directly captured by the Keap1 homodimer and degraded through the ubiquitin-proteasome pathway. Under oxidative stress conditions, Nrf2 avoids Keap1-mediated degradation because Keap1 is denatured by ROS or electrophiles (e). Stabilized Nrf2 is translocated into the nucleus and forms heterodimers with small Maf (sMaf) proteins, enabling binding to CsMBE in the promoters or enhancers of antioxidant genes (listed in the red box); transcription of these genes is induced by the Nrf2 complex containing CBP, BRG1, CHD6, and MED16. HMOX1, heme oxygenase 1; NQO1, NADPH quinone oxidoreductase 1; TXNRD1, thioredoxin reductase 1; G6PD, glucose-6-phosphate dehydrogenase; PGD, 6-phosphogluconate dehydrogenase; ME1, malic enzyme 1; GCLC, glutamate cysteine ligase catalytic subunit; GCLM, glutamate cysteine ligase modifier subunit; GSTM1, glutathione S-transferase µ1; CPT1A, carnitine palmitoyltransferase 1A; MTHFD2, methylenetetrahydrofolate dehydrogenase 2; NRF1, nuclear respiratory factor 1.
Ijms 21 02951 g002
Ijms 21 02951 g003 550
Figure 3. Impact of genetic and pharmacological modification of Nrf2 activity on kidney damage caused by IRI. Elastica-Masson staining of mouse kidney sections 14 days after renal IRI surgery distinguishes damaged renal tubules (pale pink) from undamaged renal tubules (deep pink) [67]. (A) In the outer medulla (OM), most tubules in wild-type and Nrf2-KO mice are damaged, while those in Keap1-KD and adult-onset, tubule-specific, Keap1 knockout (Tubular Keap1-KO) mice are well preserved. In the renal cortex (Cor), the damaged area is expanded in the Nrf2-KO mouse compared to that in the wild-type mouse. (B) The Nrf2 activator CDDO-imidazolide (30 µmol/kg body weight) was orally administered on the indicated days after renal IRI surgery, and kidney samples were obtained 14 days after the surgery. Notably, the data indicate that CDDO-imidazolide treatment in the early stages (1, 3 and 5 days) but not the later stages (7, 9, 11 and 13 days) after surgery is effective for renoprotection [67].
Figure 3. Impact of genetic and pharmacological modification of Nrf2 activity on kidney damage caused by IRI. Elastica-Masson staining of mouse kidney sections 14 days after renal IRI surgery distinguishes damaged renal tubules (pale pink) from undamaged renal tubules (deep pink) [67]. (A) In the outer medulla (OM), most tubules in wild-type and Nrf2-KO mice are damaged, while those in Keap1-KD and adult-onset, tubule-specific, Keap1 knockout (Tubular Keap1-KO) mice are well preserved. In the renal cortex (Cor), the damaged area is expanded in the Nrf2-KO mouse compared to that in the wild-type mouse. (B) The Nrf2 activator CDDO-imidazolide (30 µmol/kg body weight) was orally administered on the indicated days after renal IRI surgery, and kidney samples were obtained 14 days after the surgery. Notably, the data indicate that CDDO-imidazolide treatment in the early stages (1, 3 and 5 days) but not the later stages (7, 9, 11 and 13 days) after surgery is effective for renoprotection [67].
Ijms 21 02951 g003
Ijms 21 02951 g004 550
Figure 4. Mechanism underlying the intervention by Nrf2 activation in oxidative kidney injury. (A) Schematic model showing that Nrf2 protects kidneys from IRI (see Figure 1). Pharmacological inactivation of Keap1 after IRI is effective in protecting kidneys from oxidative injury by inducing the expression of antioxidative genes, which are targets of Nrf2 (see Figure 2). (B) Epo-deficiency anemia aggravates IRI-induced damage in kidneys. Elastica-Masson staining of the injured and contralateral kidneys from the anemic and normal mice 14 days after unilateral renal IRI demonstrates that the pale pink damaged area expands in the injured kidney of the mouse model for Epo-deficiency anemia compared to that of the normal control mouse. (C) Expression of the Col1a1 and Fn1 genes (encoding type-1α1 collagen and fibronectin, respectively) in injured (i) and contralateral (c) kidneys from anemic and normal mice 14 days after unilateral renal IRI surgery demonstrates that Epo-deficiency anemia aggravates kidney fibrosis. Notably, the expression levels of these fibrosis-related genes are very low in the uninjured contralateral kidneys. (D) The Nrf2 activator CDDO-imidazolide enhances renal Epo gene activity induced by anemic conditions. CDDO-imidazolide (30 µmol/kg body weight) was orally administered to anemic and normal mice on days 1 and 3 and then, RNA samples from kidneys were prepared on day 4. Since the Epo gene was replaced with GFP (green fluorescent protein) cDNA in the anemic mice, the renal Epo gene activity was estimated with the expression levels of the GFP gene. In the control mice, the Epo gene was heterozygously replaced with GFP cDNA [111]. n = 3 (C) and n = 5 (D) per group. The data are shown as the mean with standard deviations (C and D). p  <  0.01 (green line) and p  <  0.05 (orange line) among the groups, determined by the Tukey-Kramer highest significance difference test (C and D).
Figure 4. Mechanism underlying the intervention by Nrf2 activation in oxidative kidney injury. (A) Schematic model showing that Nrf2 protects kidneys from IRI (see Figure 1). Pharmacological inactivation of Keap1 after IRI is effective in protecting kidneys from oxidative injury by inducing the expression of antioxidative genes, which are targets of Nrf2 (see Figure 2). (B) Epo-deficiency anemia aggravates IRI-induced damage in kidneys. Elastica-Masson staining of the injured and contralateral kidneys from the anemic and normal mice 14 days after unilateral renal IRI demonstrates that the pale pink damaged area expands in the injured kidney of the mouse model for Epo-deficiency anemia compared to that of the normal control mouse. (C) Expression of the Col1a1 and Fn1 genes (encoding type-1α1 collagen and fibronectin, respectively) in injured (i) and contralateral (c) kidneys from anemic and normal mice 14 days after unilateral renal IRI surgery demonstrates that Epo-deficiency anemia aggravates kidney fibrosis. Notably, the expression levels of these fibrosis-related genes are very low in the uninjured contralateral kidneys. (D) The Nrf2 activator CDDO-imidazolide enhances renal Epo gene activity induced by anemic conditions. CDDO-imidazolide (30 µmol/kg body weight) was orally administered to anemic and normal mice on days 1 and 3 and then, RNA samples from kidneys were prepared on day 4. Since the Epo gene was replaced with GFP (green fluorescent protein) cDNA in the anemic mice, the renal Epo gene activity was estimated with the expression levels of the GFP gene. In the control mice, the Epo gene was heterozygously replaced with GFP cDNA [111]. n = 3 (C) and n = 5 (D) per group. The data are shown as the mean with standard deviations (C and D). p  <  0.01 (green line) and p  <  0.05 (orange line) among the groups, determined by the Tukey-Kramer highest significance difference test (C and D).
Ijms 21 02951 g004
Table
Table 1. Summary of mouse genetic analyses elucidating the roles of the Keap1-Nrf2 system in kidney disease.
Table 1. Summary of mouse genetic analyses elucidating the roles of the Keap1-Nrf2 system in kidney disease.
MousePhenotype in Kidney DiseaseReferences
Nrf2-KO
(systemic)		Vulnerable to kidney disease models
(autoimmune nephritis, diabetic nephropathy, toxic injury, ureteral obstruction, podocyte injury, and IRI)		[56,57,58,59,60,61,62,63,64,65,66,67]
Resistant to kidney disease models
(autoimmune nephritis and diabetic nephropathy)		[71,72]
Keap1-KD
(systemic)		Resistant to kidney disease models
(ureteral obstruction, podocyte injury, and IRI)		[63,64,67]
Keap1-KO
(myeloid cell)		No remarkable effect against renal IRI.[67]
(T cell)Resistant to IRI[66]
(developing tubule)Hydronephrosis in neonates[69,70]
(adult tubule)Resistant to IRI[67]
Table
Table 2. Examples of Nrf2-activating reagents experimentally tested in kidney disease models.
Table 2. Examples of Nrf2-activating reagents experimentally tested in kidney disease models.
CompoundKidney Disease ModelOutcomeReference
CDDO-imidazolideIRI (m)Improved[65,67]
CDDO-MEIRI (m), toxic injury (m), and proteinuria-induced tubular damage (m)Improved[82,83,84]
CurcuminToxic injury (r, m) and 5/6 nephrectomy (r)Improved[85,86,87,88,89]
DexmedetomidineLipopolysaccharide-induced injury (r)Improved[90]
Dimethyl fumarateToxic injury (r) and ureteral obstruction (m)Improved[91,92]
FarrerolToxic injury (r)Improved[93]
OmaveloxoloneIRI (m)Improved[94]
PaeonolToxic injury (m)Improved[95]
ResveratrolIRI (r) and aging-related injury (m)Improved[96,97]
RoxadustatToxic injury (m)Improved[98]
SB216763Toxic injury (m)Improved[99]
SulforaphaneIRI (m), pristane-induced Lupus nephritis (m), and contrast-induced nephropathy (r)Improved[100,101,102]
m, mouse; r, rat.
Table
Table 3. Clinical trials investigating CDDO-ME in diabetic CKD patients.
Table 3. Clinical trials investigating CDDO-ME in diabetic CKD patients.
PhasePeriodCKD StageRegistration ID
BEAMII2009–20103–4NCT00811889
BEACONIII2011–2012 †4NCT01351675
TSUBAKIII2015–20173–4NCT02316821
AYAMEIII2018–20223–4NCT03550443
† Halted due to a high incidence of cardiovascular events.

Share and Cite

MDPI and ACS Style

Nezu, M.; Suzuki, N. Roles of Nrf2 in Protecting the Kidney from Oxidative Damage. Int. J. Mol. Sci. 2020, 21, 2951. https://doi.org/10.3390/ijms21082951

AMA Style

Nezu M, Suzuki N. Roles of Nrf2 in Protecting the Kidney from Oxidative Damage. International Journal of Molecular Sciences. 2020; 21(8):2951. https://doi.org/10.3390/ijms21082951

Chicago/Turabian Style

Nezu, Masahiro, and Norio Suzuki. 2020. "Roles of Nrf2 in Protecting the Kidney from Oxidative Damage" International Journal of Molecular Sciences 21, no. 8: 2951. https://doi.org/10.3390/ijms21082951

APA Style

Nezu, M., & Suzuki, N. (2020). Roles of Nrf2 in Protecting the Kidney from Oxidative Damage. International Journal of Molecular Sciences, 21(8), 2951. https://doi.org/10.3390/ijms21082951

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop